HealthMore in Health→
FDA Plans Outside Review of Broader Access to Certain Peptides
Key Takeaways
- The FDA plans an outside advisory discussion on broader access to certain peptides.
- The question centers on whether compounding pharmacies should be allowed wider manufacturing room.
- The move signals that peptide access has become a significant regulatory issue.
DE
DT Editorial Team··via statnews.com
